CeleCor Therapeutics
Oana Cociorva is a seasoned professional with extensive experience in corporate planning and administration. Currently serving as the Senior Director of Corporate Planning and Administration at CeleCor Therapeutics since February 2018, Oana previously held the position of Project Manager at Instrumentation Laboratory from March 2016 to January 2018. Oana's career includes roles as a Project Management Consultant at Tem Systems and as a Safety Procedures and Regulations Consultant as well as a Senior Research Scientist at ActivX Biosciences. Earlier experience includes positions as a Postdoctoral Researcher at both Sanford Burnham Prebys Medical Discovery Institute and Optimer Pharmaceuticals. Oana holds a PhD in Chemistry from The Ohio State University and a B.S. in Chemical Engineering from the University POLITEHNICA of Bucharest.
This person is not in any teams
CeleCor Therapeutics
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and laterdevelopment of heart failure.